Prevalence of β₂-agonist inhalation for outpatients in a pediatric emergency center during enterovirus D68 epidemic
10.5415/apallergy.2018.8.e16
- Author:
Masafumi ZAITSU
1
;
Tatsuhiro MIZOGUCHI
;
Muneaki MATSUO
;
Toshimitsu TAKAYANAGI
;
Okito SHIMADA
;
Tsuneyoshi BABA
Author Information
1. Department of Pediatrics, National Hospital Organization Ureshino Medical Center, Saga, Japan. zaitsum@aol.com
- Publication Type:Original Article
- Keywords:
Enterovirus D68;
Bronchial asthma;
β₂-agonist inhalation
- MeSH:
Asthma;
Emergencies;
Enterovirus;
Hospitalization;
Humans;
Inhalation;
Japan;
Outpatients;
Prevalence
- From:
Asia Pacific Allergy
2018;8(2):e16-
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Enterovirus D68 (EV-D68) has been reported to have caused severe bronchial asthma attacks and hospitalization epidemics in Japan in September 2015. OBJECTIVE: To investigate the prevalence of β2-agonist inhalation in a pediatric emergency center during a period of increased hospitalization for bronchial asthma, which was suggested to be associated with EV-D68. METHODS: We investigated the prevalence of β2-agonist inhalation in a pediatric emergency center in Saga city, Japan, from April 2013 to October 2015, and also clarified the trends in bronchial asthma hospitalization in the same area during that time. RESULTS: The prevalence of β2-agonist inhalation in the pediatric emergency center, September 2015 was highest when EV-D68 became widespread. The monthly average for β2-agonist inhalation during the study period was 91 cases, but the count in September 2015 was 255 cases. Hospitalized cases of bronchial asthma in September 2015 were increased for age ≥3 years and not increased for age <3 years, but the prevalence of β2-agonist inhalation at the pediatric emergency center was increased even under the age of 3 years. CONCLUSION: During the epidemic period for EV-D68, cases requiring β2-agonist inhalation were increased. The EV-D68 epidemic may be related to not only severe cases requiring hospitalization, but also exacerbation of relatively mild symptoms of bronchial asthma.
